Join
Live feed
·
PRReleasevia Quantisnow
Allogene Therapeutics Inc. logo
Natera Inc. logo

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
ALLO· Allogene Therapeutics Inc.NTRA· Natera Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALLO (Allogene Therapeutics Inc.), NTRA (Natera Inc.) and more on Quantisnow.